Jane Huang - 04 Oct 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
President, CMO
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
04 Oct 2023
Net transactions value
$0
Form type
4
Filing time
06 Oct 2023, 09:07:55 UTC
Previous filing
06 Jul 2023
Next filing
08 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise +9,375 +31% 39,728 04 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Restricted Stock Unit Options Exercise $0 +9,375 +11% $0.000000 93,750 04 Oct 2023 Common Stock 9,375 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2 The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.